Skip to Content

Granix Approval History

Granix (tbo-filgrastim) is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

Development History and FDA Approval Process for Granix

Dec 23, 2014Approval FDA Approves Teva’s Granix (tbo-filgrastim) Injection for Self-Administration
Aug 30, 2012Approval FDA Approves Tbo-filgrastim for Severe Neutropenia in Certain Cancer Patients
Feb  2, 2010Teva Announces FDA Accepts BLA for XM02
Dec  2, 2009Teva Announces the Submission of a Biologics License Application (BLA) for XM02 for the Treatment of Chemotherapy-Induced Neutropenia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.